Literature DB >> 11585271

The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine.

M P Davis1, J Homsi.   

Abstract

The enzymes in the cytochrome p450 monooxygenase system (CYP) are the major enzymes responsible for metabolizing medications. The CYP2D6 isomer is responsible for metabolizing certain opioids, neuroleptics, antidepressants and cardiac medications. Owing to CYP2D6's low capacity and high affinity it is easily saturated by substrate and/or inhibited, resulting in pharmacokinetic interactions. Polymorphisms of the structural gene are common, leading to wide inter-individual and ethnic differences in drug metabolism. Clinically important drug interactions, which may be anticipated in the palliative medicine population, are reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585271     DOI: 10.1007/s005200000222

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  12 in total

Review 1.  Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies.

Authors:  Petra Feyer; M Heinrich Seegenschmiedt; Maria Steingraeber
Journal:  Support Care Cancer       Date:  2005-07-26       Impact factor: 3.603

2.  Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics.

Authors:  Patrick Thurner; Christian Nanoff
Journal:  Breast Care (Basel)       Date:  2008-11-25       Impact factor: 2.860

3.  Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial.

Authors:  Rebecca C Pierson; Brandon T Gufford; Zeruesenay Desta; Michael T Eadon
Journal:  Pharmacogenomics       Date:  2017-06-08       Impact factor: 2.533

Review 4.  Demographics, assessment and management of pain in the elderly.

Authors:  Mellar P Davis; Manish Srivastava
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients.

Authors:  Cesare Gridelli; Matti Aapro
Journal:  Support Care Cancer       Date:  2004-03-04       Impact factor: 3.603

6.  Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans.

Authors:  Gang Xie; Dingying Zhou; Ka-Wing Cheng; Chi C Wong; Basil Rigas
Journal:  Biochem Pharmacol       Date:  2013-02-08       Impact factor: 5.858

Review 7.  Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?

Authors:  Morgan Trammel; Mary Roederer; Jai Patel; Howard McLeod
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

8.  Adult cancer pain.

Authors:  Robert A Swarm; Amy Pickar Abernethy; Doralina L Anghelescu; Costantino Benedetti; Sorin Buga; Charles Cleeland; Oscar A Deleon-Casasola; June G Eilers; Betty Ferrell; Mark Green; Nora A Janjan; Mihir M Kamdar; Michael H Levy; Maureen Lynch; Rachel M McDowell; Natalie Moryl; Suzanne A Nesbit; Judith A Paice; Michael W Rabow; Karen L Syrjala; Susan G Urba; Sharon M Weinstein; Mary Dwyer; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2013-08       Impact factor: 11.908

Review 9.  Opioids: a review.

Authors:  Eric Chevlen
Journal:  Curr Pain Headache Rep       Date:  2003-02

10.  Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.

Authors:  Trine Naalsund Andreassen; Pål Klepstad; Andrew Davies; Kristin Bjordal; Staffan Lundström; Stein Kaasa; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2010-12-08       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.